Home  »  Companies   »  New Big Money Means Kintara Therapeutics Inc. (KTR...

New Big Money Means Kintara Therapeutics Inc. (KTRA) Investors Could Reap Benefit

Kintara Therapeutics Inc. (NASDAQ: KTRA) is -71.27% lower on its value in year-to-date trading and has touched a low of $0.14 and a high of $1.53 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The KTRA stock was last observed hovering at around $0.15 in the last trading session, with the day’s loss setting it 0.0%.

Currently trading at $0.15, the stock is -6.08% and -20.27% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.04 million and changing -2.33% at the moment leaves the stock -54.05% off its SMA200. KTRA registered -88.90% loss for a year compared to 6-month loss of -61.40%.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now.


The stock witnessed a -12.38% gain in the last 1 month and extending the period to 3 months gives it a -41.87%, and is -8.44% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.68% over the week and 9.21% over the month.

Fwd P/E is 4.88. Distance from 52-week low is 7.80% and -90.42% from its 52-week high.

Kintara Therapeutics Inc. (KTRA) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Kintara Therapeutics Inc. (KTRA) is a “Hold”. 1 analysts offering their recommendations for the stock have an average rating of 2.30, where 1 rate it as a Hold and 0 think it is a “Overweight”. 0 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

The EPS is expected to shrink by -83.30% this year

Kintara Therapeutics Inc. (KTRA) Top Institutional Holders

The shares outstanding are 65.53M, and float is at 59.29M with Short Float at 1.54%.

Kintara Therapeutics Inc. (KTRA) Insider Activity

A total of 3 insider transactions have happened at Kintara Therapeutics Inc. (KTRA) in the last six months, with sales accounting for 0 and purchases happening 3 times. The most recent transaction is an insider purchase by Hoffman Robert E., the company’s President and CEO. SEC filings show that Hoffman Robert E. bought 55,000 shares of the company’s common stock on Feb 15 at a price of $0.47 per share for a total of $25795.0. Following the purchase, the insider now owns 55000.0 shares.

Kintara Therapeutics Inc. disclosed in a document filed with the SEC on Dec 08 that Praill Anthony Scott (Chief Financial Officer) bought a total of 28,700 shares of the company’s common stock. The trade occurred on Dec 08 and was made at $0.68 per share for $19430.0. Following the transaction, the insider now directly holds 37186.0 shares of the KTRA stock.

Still, SEC filings show that on Dec 07, Zarrabian Saiid (Head of Strategic Partnerships) acquired 38,109 shares at an average price of $0.64 for $24298.0. The insider now directly holds 55,500 shares of Kintara Therapeutics Inc. (KTRA).

Most Popular

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Posts




The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.